MedImmune Ventures, the corporate venturing division of biotechnology researcher MedImmune, has taken part in a $47m series C round for US-based clinical-stage pharmaceutical company G1 Therapeutics.
The round was led by Cormorant Asset Management and also featured Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments, Rock Springs Capital, Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, Mountain Group Capital, RA Capital and Tavistock Life Sciences.
Founded in 2012, G1 Therapeutics is a spinout of North Carolina University’s Lineberger Comprehensive Cancer…
